Committee for Medicinal Products for Human Use (CHMP)

EMA Reviewing Approval of Novartis’ Adakveo

The European Medicines Agency (EMA) said its Committee for Medicinal Products for Human Use (CHMP) has begun reviewing its marketing authorization for Novartis’ Adakveo, a medicine to prevent vaso-occlusive pain crises in patients with sickle cell disease.

EMA’s CHMP Greenlights Omicron-1 Vaccines

The human medicines committee (CHMP) of EU drug regulator European Medicines Agency (EMA) has recommended approval of the updated Covid-19 vaccines of Pfizer-BioNTech and Moderna, combining protection against the original Omicron variant as well as the wild type that emerged in China in early 2020.

EU Approves Sales of Sanofi’s New Diabetes Drug

Japan’s Eisai Gets EU Nod for Thyroid Cancer Drug